United States

SHERIDAN, WYOMING - November 25, 2025 - Philips has received U.S. FDA 510(k) clearance for the latest release of its Cardiovascular Workspace (IntelliSpace Cardiovascular, ISCV), enabling U.S. health systems to deploy the cardiovascular imaging and information management platform as a cloud-hosted, SaaS solution on Philips HealthSuite. The move positions hospitals and cardiology networks to modernize IT, scale integrated diagnostics, and accelerate real-world adoption of AI-enabled cardiovascular workflows.

Cloud-based cardiovascular informatics for U.S. health systems

SHERIDAN, WYOMING - November 25, 2025 - Nestlé Health Science is deepening its open innovation strategy in nutrition and health through a series of academic and startup collaborations focused on women's health, healthy longevity and weight management, positioning itself at the center of fast-growing therapeutic nutrition markets. By linking university-based science, entrepreneurial talent and its own R&D capabilities, the company aims to accelerate the translation of emerging technologies into differentiated nutritional solutions for consumers and patients.

SHERIDAN, WYOMING - November 13, 2025 - Dentsply Sirona is strengthening its long-term commitment to increasing oral-health access for U.S. veterans, deepening its partnership with Dental Lifeline Network (DLN) and activating employee-driven support initiatives across the country. The renewed collaboration aligns with the company's global sustainability strategy and reflects a growing corporate focus on social-impact programs that directly address care gaps in underserved populations.

Strengthening a Decades-Long Collaboration

Dentsply Sirona and DLN have worked together since 1999, forming one of the dental industry's most enduring corporate-nonprofit collaborations. Entering its 26th year, the partnership includes direct financial support, in-kind product donations and professional-volunteer mobilization through Dentsply Sirona's VETERANS@DS employee resource group.

SHERIDAN, WYOMING - November 13, 2025 - Pfizer has completed its $7 billion acquisition of Metsera, securing a set of differentiated obesity and cardiometabolic candidates as regulatory momentum accelerates around metabolic disease innovation in the United States. The deal positions Pfizer at the center of one of the most politically scrutinized and fastest-growing therapeutic markets, as federal leaders push for expanded access and a stronger domestic pipeline in obesity care.

SHERIDAN, WYOMING - November 13, 2025 - As the TrumpRx platform approaches launch in early 2026, U.S. drugmakers are rolling out targeted direct-to-consumer pricing for a carefully chosen mix of dermatology, respiratory, cardiovascular, immunology, and metabolic products. While the discounts generate attention, analysts say their commercial impact varies sharply by drug class, revenue cycle, and therapeutic demand-revealing a strategic pattern rather than a broad affordability shift.

Discounting Patterns Reveal Manufacturers' Portfolio Priorities
Pfizer, AstraZeneca, Amgen, Bristol Myers Squibb, Novo Nordisk, and Lilly have each chosen different subsets of products for deep DTC price cuts. Across these offerings, a clear pattern emerges: brands with declining growth, approaching patent expirations, or limited payer friction are overrepresented.

SHERIDAN, WYOMING - November 13, 2025 - Major pharmaceutical companies are rapidly rolling out direct-to-consumer (DTC) pricing programs ahead of the federal TrumpRx platform's debut in early 2026, signaling a shift in commercial strategy as manufacturers seek to bypass traditional intermediaries and regain control of how patients access branded therapies. Yet analysts warn that these channels-despite deep headline discounts-may offer only marginal financial relief to most patients and are unlikely to dent overall U.S. drug spending.

SHERIDAN, WYOMING - November 13, 2025 - As the federal government prepares to launch its TrumpRx direct-to-consumer platform in early 2026, U.S. drugmakers are accelerating their own discount initiatives in anticipation of sweeping pricing reforms tied to the Most Favored Nation (MFN) framework. Yet analysts and health economists warn that these programs-ranging from discounted dermatology creams to multi-billion-dollar GLP-1 therapies-may have limited influence on overall spending, with most insured patients unlikely to shift away from existing payer pathways.

SHERIDAN, WYOMING - November 13, 2025 - Drug manufacturers are urging the FDA to broaden its proposed PreCheck program beyond new factory construction, warning that excluding existing facilities could slow U.S. efforts to expand pharmaceutical production capacity. At a recent agency meeting, representatives from companies spanning gene therapy, generics, and biologics argued that PreCheck's current scope overlooks the fastest route to alleviating drug shortages and strengthening domestic supply chains.

Early-Stage Regulatory Support Designed Only for New Sites
PreCheck was introduced to streamline the regulatory oversight of newly built manufacturing plants, giving participating companies earlier FDA engagement well before their first commercial product application. The program is meant to make U.S. construction more attractive by reducing uncertainty and aligning expectations early in the buildout process.

SHERIDAN, WYOMING - November 13, 2025 - In a sweeping regulatory shift with major implications for women's health providers, pharmaceutical manufacturers, and payers, the FDA has removed the black box warning from all hormone replacement therapy (HRT) products. The reversal ends a 22-year stance shaped by the early 2000s Women's Health Initiative (WHI) trial and opens the door to renewed clinical adoption and investment across the growing HRT market.

SHERIDAN, WYOMING - November 13, 2025 - Amgen has introduced a new U.S. direct-to-patient model that aims to make Repatha more affordable and accessible to adults at elevated cardiovascular risk. The initiative, called AmgenNow, offers a nearly 60% price reduction and removes common payer-driven barriers-an unusual move in the cardiometabolic market and one that could ripple across manufacturers, payers, and care-delivery partners seeking more predictable access pathways.